BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 19454817)

  • 1. Phenotypic CYP2A6 variation and the risk of pancreatic cancer.
    Kadlubar S; Anderson JP; Sweeney C; Gross MD; Lang NP; Kadlubar FF; Anderson KE
    JOP; 2009 May; 10(3):263-70. PubMed ID: 19454817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2A6 activity determined by caffeine phenotyping: association with colorectal cancer risk.
    Nowell S; Sweeney C; Hammons G; Kadlubar FF; Lang NP
    Cancer Epidemiol Biomarkers Prev; 2002 Apr; 11(4):377-83. PubMed ID: 11927498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel markers of susceptibility to carcinogens in diet: associations with colorectal cancer.
    Sweeney C; Coles BF; Nowell S; Lang NP; Kadlubar FF
    Toxicology; 2002 Dec; 181-182():83-7. PubMed ID: 12505289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between CYP2A6 genetic polymorphisms and lung cancer: a meta-analysis of case-control studies.
    Liu T; Xie CB; Ma WJ; Chen WQ
    Environ Mol Mutagen; 2013 Mar; 54(2):133-40. PubMed ID: 23203414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population.
    Tan W; Chen GF; Xing DY; Song CY; Kadlubar FF; Lin DX
    Int J Cancer; 2001 Mar; 95(2):96-101. PubMed ID: 11241319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers.
    Ariyoshi N; Miyamoto M; Umetsu Y; Kunitoh H; Dosaka-Akita H; Sawamura Y; Yokota J; Nemoto N; Sato K; Kamataki T
    Cancer Epidemiol Biomarkers Prev; 2002 Sep; 11(9):890-4. PubMed ID: 12223434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK.
    Wang H; Tan W; Hao B; Miao X; Zhou G; He F; Lin D
    Cancer Res; 2003 Nov; 63(22):8057-61. PubMed ID: 14633739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of total meat intake and exposure to individual heterocyclic amines in a case-control study of colorectal cancer: contribution of metabolic variation to risk.
    Nowell S; Coles B; Sinha R; MacLeod S; Luke Ratnasinghe D; Stotts C; Kadlubar FF; Ambrosone CB; Lang NP
    Mutat Res; 2002 Sep; 506-507():175-85. PubMed ID: 12351157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of human cytochrome P450 (CYP) in the metabolic activation of nitrosamine derivatives: application of genetically engineered Salmonella expressing human CYP.
    Kamataki T; Fujita K; Nakayama K; Yamazaki Y; Miyamoto M; Ariyoshi N
    Drug Metab Rev; 2002 Aug; 34(3):667-76. PubMed ID: 12214673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers.
    Fujieda M; Yamazaki H; Saito T; Kiyotani K; Gyamfi MA; Sakurai M; Dosaka-Akita H; Sawamura Y; Yokota J; Kunitoh H; Kamataki T
    Carcinogenesis; 2004 Dec; 25(12):2451-8. PubMed ID: 15308589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population.
    Djordjevic N; Carrillo JA; Gervasini G; Jankovic S; Aklillu E
    Eur J Clin Pharmacol; 2010 Jun; 66(6):571-8. PubMed ID: 20155256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P450 2A6 phenotyping based on dietary caffeine intake in a Japanese population of non-smokers.
    Kimura M; Shimizu M; Kiyotani K; Nakagawa K; Kamataki T; Yamazaki H
    Drug Metab Lett; 2012 Jun; 6(2):67-72. PubMed ID: 22849705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population.
    Loriot MA; Rebuissou S; Oscarson M; Cenée S; Miyamoto M; Ariyoshi N; Kamataki T; Hémon D; Beaune P; Stücker I
    Pharmacogenetics; 2001 Feb; 11(1):39-44. PubMed ID: 11207029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lung cancer risk in relation to nicotinic acetylcholine receptor, CYP2A6 and CYP1A1 genotypes in the Bangladeshi population.
    Islam MS; Ahmed MU; Sayeed MS; Maruf AA; Mostofa AG; Hussain SM; Kabir Y; Daly AK; Hasnat A
    Clin Chim Acta; 2013 Feb; 416():11-9. PubMed ID: 23178447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous action of the flavonoid quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, N-acetyltransferase and xanthine oxidase activity in healthy volunteers.
    Chen Y; Xiao P; Ou-Yang DS; Fan L; Guo D; Wang YN; Han Y; Tu JH; Zhou G; Huang YF; Zhou HH
    Clin Exp Pharmacol Physiol; 2009 Aug; 36(8):828-33. PubMed ID: 19215233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2A6 deletion polymorphism is associated with decreased susceptibility of lung cancer in Asian smokers: a meta-analysis.
    Liu YL; Xu Y; Li F; Chen H; Guo SL
    Tumour Biol; 2013 Oct; 34(5):2651-7. PubMed ID: 23649654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparisons of CYP2A6 genotype and enzyme activity between Swedes and Koreans.
    Djordjevic N; Carrillo JA; van den Broek MP; Kishikawa J; Roh HK; Bertilsson L; Aklillu E
    Drug Metab Pharmacokinet; 2013; 28(2):93-7. PubMed ID: 22850738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between cancer risk and drug-metabolizing enzyme gene (CYP2A6, CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1) polymorphisms in cases of lung cancer in Japan.
    Tamaki Y; Arai T; Sugimura H; Sasaki T; Honda M; Muroi Y; Matsubara Y; Kanno S; Ishikawa M; Hirasawa N; Hiratsuka M
    Drug Metab Pharmacokinet; 2011; 26(5):516-22. PubMed ID: 21791872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of cigarette smoking and exposure to cadmium and lead on phenotypic variability of hepatic CYP2A6 and renal function biomarkers in men.
    Satarug S; Ujjin P; Vanavanitkun Y; Nishijo M; Baker JR; Moore MR
    Toxicology; 2004 Nov; 204(2-3):161-73. PubMed ID: 15388242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China.
    Song DK; Xing DL; Zhang LR; Li ZX; Liu J; Qiao BP
    Cancer Detect Prev; 2009; 32(5-6):416-23. PubMed ID: 19303722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.